Hong Kong strengthens its pharmaceutical oversight infrastructure by appointing Li Zili, a seasoned FDA veteran, as head of its newly established medical products regulatory authority. This strategic move reflects the region's commitment to enhancing drug safety standards and expediting approval processes for innovative therapies. Zili's three-year mandate will focus on developing robust regulatory frameworks, aligning Hong Kong's practices with international best practices, and positioning the territory as a trusted hub for medical innovation and patient protection in Asia-Pacific.

Summary auto-generated by AI from the original publisher's content. Editorial standards.